Exelixis, Inc.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients…
Biotechnology
US, Alameda [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer GroupA quick analysis that compared Exelixis, Inc. (EXEL) to it's peer group, including competitors as well as it's industry. All monetary values in mil. except volume - volume is in thousands.
| Company | Price | Change | Volume, Avg. | Market Cap. | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 39,110.72 | 13,796.00 | 637.92 | 501.66 | -1,139.54 | 0.00 | 12.4988 | 45.11 | -0.9018 | -21.1029 | -0.08 | -0.10 | 7.0484 | - - | ||
| Maximum | - - | - - | - - | 1,535,067.00 | 609,984.00 | 35,800.00 | 99,050.00 | 5,421.00 | 0.02 | 701.8537 | 2,849.43 | 3.0051 | 85.3485 | 0.15 | 8.35 | 61.5621 | - - | ||
| Minimum | - - | - - | - - | 0.00 | 0.00 | -10,603.00 | -56,335.00 | -50,658.00 | 0.00 | -164.8536 | -132.82 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0844 | - - | ||
| Krystal Biotech, Inc. KRYS | 190.40 | 8.11 4.45% | 222 vs. 226 | 5,475.00 | 45.00 | 0.00 | 14.00 | -268.00 | 0.0300 | 1336.3467 | 0.0000 | 0.9465 | 0.0206 | 0.0012 | 0.0011 | 12.2870 | 28.00 | ||
| Reata Pharmaceuticals, Inc. RETA | 172.36 | 0.04 0.02% | 1,909 vs. 954 | 6,566.00 | 22.00 | 192.00 | -70.00 | -1,490.00 | 5.1200 | 5.4820 | 0.0000 | 0.9628 | 8.4849 | 2.2110 | 0.3840 | 2.8209 | 38.00 | ||
| BioMarin Pharmaceutical Inc. BMRN | 64.26 | 0.81 1.28% | 1,195 vs. 1,759 | 12,246.00 | 648.00 | 88.00 | 12.00 | -532.00 | 0.4700 | 46.3847 | 0.0000 | 0.7850 | 0.1366 | 0.0175 | 0.0129 | 1.5477 | 190.00 | ||
| Alnylam Pharmaceuticals, Inc. ALNY | 244.89 | -1.91 -0.77% | 450 vs. 862 | 31,586.00 | 494.00 | -65.00 | -94.00 | -7,075.00 | -0.5200 | -73.3326 | 0.0000 | 0.8665 | -0.1334 | 0.3007 | -0.0172 | 2.8593 | 128.00 | ||
| Sarepta Therapeutics, Inc. SRPT | 114.23 | 3.73 3.38% | 872 vs. 866 | 10,911.00 | 413.00 | 36.00 | -284.00 | -4,410.00 | 0.3800 | 83.5325 | 0.0000 | 0.8777 | 0.0874 | 0.0376 | 0.0112 | 2.9737 | 95.00 | ||
| PTC Therapeutics, Inc. PTCT | 43.23 | 0.34 0.79% | 534 vs. 718 | 3,334.00 | 210.00 | -91.00 | 6.00 | -3,375.00 | -1.2000 | -5.9705 | 0.0000 | 0.6846 | -0.4358 | 0.1024 | -0.0512 | 1.8854 | 77.00 | ||
| Seagen Inc. SGEN | 228.74 | -0.16 -0.07% | 19,392 vs. 1,634 | 43,154.00 | 648.00 | -215.00 | -79.00 | -2,756.00 | -1.1500 | -46.2406 | 0.0000 | 0.7452 | -0.3327 | -0.0846 | -0.0594 | 1.9572 | 188.00 | ||
| TG Therapeutics, Inc. TGTX | 35.07 | 0.52 1.51% | 2,573 vs. 3,764 | 5,459.00 | 63.00 | -10.00 | -8.00 | -1,525.00 | -0.0732 | -50.4229 | 0.0000 | 0.9130 | -0.1687 | -0.0669 | -0.0287 | 2.7564 | 155.00 | ||
| Madrigal Pharmaceuticals, Inc. MDGL | 347.45 | 18.21 5.53% | 532 vs. 380 | 7,578.00 | 0.00 | -147.00 | -149.00 | -1,483.00 | -7.3800 | -8.6674 | 0.0000 | 0.0000 | 0.0000 | -0.1734 | -0.1363 | 9.2623 | 21.00 | ||
| Halozyme Therapeutics, Inc. HALO | 49.00 | 3.30 7.22% | 4,509 vs. 1,586 | 6,234.00 | 195.00 | 76.00 | 125.00 | 167.00 | 0.6100 | 17.0691 | 0.0000 | 0.7647 | 0.3922 | 0.4321 | 0.0417 | 5.0088 | 127.00 | ||
| Exelixis, Inc. EXEL | 35.61 | 0.78 2.24% | 1,682 vs. 2,058 | 10,169.00 | 425.00 | 37.00 | 50.00 | -258.00 | 0.1200 | 47.8131 | 0.0000 | 0.9500 | 0.0878 | 0.0175 | 0.0133 | 3.2273 | 285.00 | ||
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.